Quantra®即时凝血分析仪在急诊心脏手术中的临床效用
该前瞻性研究纳入52例急诊心脏手术出血高风险成人患者,比较Quantra®即时凝血分析仪与血栓弹力图及标准实验室检测。研究显示Quantra阈值对低血小板、活化部分凝血活酶时间延长和血栓弹力图最大振幅降低具有高阴性预测值,并能预测血小板输注的临床需求,但所有检测对新鲜冰冻血浆输注需求的预测均不佳。
要点
- Quantra® fibrinogen clot stiffness 2.0 hPa对应纤维蛋白原1.5 g.l-1的输注阈值。
- Quantra® platelet clot stiffness 13.5 hPa对应血小板100,000.μl-1,阴性预测值97.4%。
- Quantra® clot time 159 s和183 s分别对应凝血酶原时间20 s和活化部分凝血活酶时间48 s。
核心结论
- Quantra®即时凝血分析仪可为急诊心脏手术的输血管理提供有用数据。
研究设计与样本
- 前瞻性研究,经伦理批准并获书面知情同意,纳入52例出血风险增加的急诊心脏手术成人患者。
主要发现
- 52例患者中34例(65%)接受了红细胞输注。
- Quantra®对低血小板的阴性预测值为97.4%(platelet clot stiffness)。
- Quantra®对活化部分凝血活酶时间延长的阴性预测值为92.6%(clot time)。
- Quantra®对血栓弹力图最大振幅降低的阴性预测值为93.6%(clot stiffness)。
- Quantra®预测血小板输注需求的曲线下面积为0.71(p=0.001)。
关键数值与推荐
- 纤维蛋白原1.5 g.l-1对应Quantra fibrinogen clot stiffness 2.0 hPa。
- 血小板100,000.μl-1对应Quantra platelet clot stiffness 13.5 hPa。
- 凝血酶原时间20 s对应Quantra clot time 159 s。
- 活化部分凝血活酶时间48 s对应Quantra clot time 183 s。
- 血栓弹力图最大振幅50 mm对应Quantra clot stiffness 17.0 hPa。
临床怎么用
- 在急诊心脏手术中可用Quantra®阈值辅助判断低血小板、凝血时间延长和血栓弹力图最大振幅降低。
- Quantra®的高阴性预测值有助于排除需要输注血小板或新鲜冰冻血浆的情况。
- Quantra®可辅助预测血小板输注需求,但不应单独用于决定新鲜冰冻血浆输注。
局限性
- 样本量52例,其中34例(65%)接受红细胞输注,样本代表性有限。
- 研究仅比较Quantra®与血栓弹力图及标准实验室检测,未评估对临床结局的影响。
- 所有检测对新鲜冰冻血浆输注需求的预测均不佳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coagulopathic bleeding during and after cardiac surgery is associated with increased morbidity and mortality. Viscoelastic testing is increasingly used instead of laboratory testing. Our aim was to compare a new viscoelastic point-of-care device, the Quantra® System, with thromboelastography and standard laboratory testing. After ethical approval and with written informed consent, we prospectively recruited adult patients undergoing urgent cardiac surgery at increased risk of bleeding. Clot time and clot stiffness values were compared before, during and after cardiopulmonary bypass. We prospectively recruited 52 patients, of whom 34 (65%) were transfused with red blood cells. Our usual transfusion thresholds for fibrinogen (1.5 g.l-1 ), platelets (100,000.μl-1 ), prothrombin time (20 s), activated partial thromboplastin time (48 s) and maximum amplitude on thromboelastography (50 mm) corresponded to Quantra values of fibrinogen clot stiffness 2.0 hPa, platelet clot stiffness 13.5 hPa, clot time 159 s, clot time 183 s and clot stiffness 17.0 hPa, respectively. These Quantra thresholds showed high negative predictive value for low platelets (platelet clot stiffness, 97.4%), prolonged activated partial thromboplastin time (clot time, 92.6%) and reduced maximum amplitude on thromboelastography (clot stiffness, 93.6%). The Quantra predicted clinical need for transfusion of platelets (area under the curve 0.71, p = 0.001) but all tests performed poorly at predicting the need for fresh frozen plasma transfusion. We have shown that point-of-care testing using the novel Quantra system provides useful data for guiding transfusion management.
引用
- Zghaibe W, Scheuermann S, Munting K, et al. Clinical utility of the Quantra® point-of-care haemostasis analyser during urgent cardiac surgery. Anaesthesia. 2019. PMID: 31845321. doi:10.1111/anae.14942
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。